RET and non-small cell lung carcinoma: The preliminary antitumor activity was observed among RET-fusion positive NSCLC patients (ESMO 2021, data cutoff on April 28, 2021).30 Here we aimed to evaluate the safety and PK profile of HA121-28 in patients with solid tumors; furthermore, the preliminary efficacy in RET fusion NSCLC patients.